Trials / Unknown
UnknownNCT06237400
A Study of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
A Phase I/II Dose Escalation and Expansion Study to Evaluating the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the safety and tolerability of ZG19018 in Patients with KRAS G12C mutant advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZG19018 | ZG19018 Given by PO (mouth) |
Timeline
- Start date
- 2022-05-26
- Primary completion
- 2025-05-01
- Completion
- 2025-05-01
- First posted
- 2024-02-01
- Last updated
- 2024-02-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06237400. Inclusion in this directory is not an endorsement.